Substituted boronic acids as antimicrobials

1. A compound of formula (III-2):

or a pharmaceutically acceptable salt thereof,

wherein:

J is CR 5 ;

L is CR 5 ;

M is CR 5 ;

each R 5 is independently selected from the group consisting of H, halogen, CN, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, —(CH 2 ) p —Y 3 —(CH 2 ) q M′, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, —C(═NR 1 )R 2 , —C(O)NR 1 R 2 , —C(O)NR 1 OR 2 , —C(O)OR 1 , —NR 1 CR 2 (═NR 3 ), —NR 1 C(═NR 2 )NR 3 R 4 , —NR 1 C(O)R 2 , —NR 1 C(O)NR 2 R 3 , —NR 1 C(O)OR 2 , —NR 1 S(O) 2 R 2 , —NR 1 S(O) 2 NR 2 R 3 , —NR 1 S(O) 2 NR 1 OR 3 , OH, O-aryl, SH, —S(O)(CH 2 ) 1-3 R 4 , —S(O) 2 NR 1 R 2 , —S(O) 2 NR 1 OR 3 , C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 5-10 membered heterocyclyl, and 5-10 membered heteroaryl;

M′ is selected from the group consisting of halogen, CN, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, —C(═NR 1 )R 2 , —C(═NR 1 )NR 2 R 3 , —C(O)NR 1 R 2 , —C(O)NR 1 OR 2 , —NR 1 CR 2 (═NR 3 ), —NR 1 C(═NR 2 )NR 3 R 4 , —NR 1 C(O)R 2 , —NR 1 C(O)NR 2 R 3 , —NR 1 C(O)OR 2 , —NR 1 S(O) 2 R 2 , —NR 1 S(O) 2 NR 2 R 3 , OH, —S(O) 2 R 1 , S(O) 2 NR 1 R 2 , —S(O) 2 NR 1 OR 3 , C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 3-10 membered heterocyclyl, and 5-10 membered heteroaryl;

Y 3 is selected from the group consisting of —CR 1 R 2 —, —NR 1 —, —O—, —S—, —S(O)—, and —S(O) 2 —;

R 1 is selected from the group consisting of H, halogen, C 1 -C 4 alkyl, OC 1 -C 4 alkyl, C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 4-10 membered heterocyclyl, and 5-10 membered heteroaryl;

R 2 is selected from the group consisting of H, halogen, C 1 -C 4 alkyl, OC 1 -C 4 alkyl, C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 4-10 membered heterocyclyl, and 5-10 membered heteroaryl;

R 3 is selected from the group consisting of H, halogen, C 1 -C 4 alkyl, OC 1 -C 4 alkyl, C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 4-10 membered heterocyclyl, and 5-10 membered heteroaryl;

R 4 is selected from the group consisting of H, halogen, C 1 -C 4 alkyl, OC 1 -C 4 alkyl, C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 4-10 membered heterocyclyl, and 5-10 membered heteroaryl;

R is selected from the group consisting of H, alkali metal cation, NH 4 + , C 1 -C 9 alkyl, —CR 10 R 11 OC(O)C 1 -C 9 alkyl, —CR 10 R 11 OC(O)NR 10 C 1 -C 9 alkyl, —CR 10 R 11 OC(O)NR 10 C 6 -C 10 aryl, —CR 10 R 11 OC(O)OC 1 - C 9 alkyl, —CR 10 R 11 OC(O)OC 6 -C 10 aryl, and —CR 10 R 11 OC(O)C 6 -C 10 aryl; or

R is

R 10 is selected from the group consisting of H, C 1 -C 4 alkyl, C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 5-10 membered heterocyclyl, and 5-10 membered heteroaryl;

R 11 is selected from the group consisting of H, C 1 -C 4 alkyl, C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 5-10 membered heterocyclyl, and 5-10 membered heteroaryl;

p is 0, 1, or 2; and

q is 0, 1, or 2;

wherein the C 1 -C 4 alkyl of M′ is optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, CN, —C(O)NR 1 R 2 , —NR 1 R 2 , —NR 1 C(O)R 2 , OR 1 , and heterocyclyl; and

wherein the C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 3-10 membered heterocyclyl, and 5-10 membered heteroaryl of M′ are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, C 1 -C 4 alkyl, —C(O)NR 1 R 2 , —NR 1 C(O)R 2 , —(CH 2 ) 0-4 CN, —(CH 2 ) 0-4 NR 1 R 2 , —(CH 2 ) 0-4 OR 1 , and —(CH 2 ) 0-4 heterocyclyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

each R 5 is independently selected from the group consisting of H, halogen, CN, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, —(CH 2 ) p —Y 3 —(CH 2 ) q M′, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, OH, O-aryl, SH, C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 5-10 membered heterocyclyl, and 5-10 membered heteroaryl;

M′ is selected from the group consisting of C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, —C(═NR 1 )R 2 , —C(═NR 1 )NR 2 R 3 , —C(O)NR 1 R 2 , —C(O)NR 1 OR 2 , —NR 1 CR 2 (═NR 3 ), —NR 1 C(═NR 2 )NR 3 R 4 , —NR 1 C(O)R 2 , —NR 1 C(O)NR 2 R 3 , —NR 1 C(O)OR 2 , —NR 1 S(O) 2 R 2 , —NR 1 S(O) 2 NR 2 R 3 , —S(O) 2 R 1 , —S(O) 2 NR 1 R 2 , —S(O) 2 NR 1 OR 3 , C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 3-10 membered heterocyclyl, and 5-10 membered heteroaryl;

Y 3 is selected from the group consisting of —CH 2 —, —NR 1 —, —O—, —S—, —S(O)—, and —S(O) 2 —;

R 1 is selected from the group consisting of H, C 1 -C 4 alkyl, C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 4-10 membered heterocyclyl, and 5-10 membered heteroaryl;

R 2 is selected from the group consisting of H, C 1 -C 4 alkyl, C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 4-10 membered heterocyclyl, and 5-10 membered heteroaryl;

R 3 is selected from the group consisting of H, C 1 -C 4 alkyl, C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 4-10 membered heterocyclyl, and 5-10 membered heteroaryl;

R 4 is selected from the group consisting of H, C 1 -C 4 alkyl, C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 4-10 membered heterocyclyl, and 5-10 membered heteroaryl;

R is selected from the group consisting of H, alkali metal cation, NH 4 + , C 1 -C 9 alkyl, —CR 10 R 11 OC(O)C 1 -C 9 alkyl, —CR 10 R 11 OC(O)OC 1 -C 9 alkyl, —CR 10 R 11 OC(O)OC 6 -C 10 aryl, and —CR 10 R 11 OC(O)C 6 -C 10 aryl; or

R is

p is 0 or 1; and

q is 0 or 1;

wherein the C 1 -C 4 alkyl of M′ is optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, —C(O)NR 1 R 2 , —NR 1 R 2 , —NR 1 C(O)R 2 , and OR 1 ; and

wherein the C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 3-10 membered heterocyclyl, and 5-10 membered heteroaryl of M′ are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, C 1 -C 4 alkyl, —C(O)NR 1 R 2 , —NR 1 C(O)R 2 , —NR 1 R 2 , and OR 1 .

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least one R 5 is independently selected from the group consisting of halogen, CN, C 1 -C 6 heteroalkyl, —(CH 2 ) p —Y 3 —(CH 2 ) q M′, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, OH, C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 5-10 membered heterocyclyl, and 5-10 membered heteroaryl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least one R 5 is independently selected from the group consisting of F, CN, CHF 2 , CF 3 , —C≡CH, —C(O)NH 2 , OH, OCH 3 , OCH 2 CH 3 , SCH 3 , and —S(O) 2 CH 3 .

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least one R 5 is independently selected from the group consisting of halogen, —C(═NR 1 )R 2 , —C(O)NR 1 R 2 , —S(O)-M′, and —S(O) 2 -M′.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least one R 5 is independently selected from the group consisting of C 2 -C 4 alkynyl, diazolyl, and triazolyl.

7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein R 5 is selected from the group consisting of

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

J is CH; and

at least one R 5 is independently selected from the group consisting of halogen, CN, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, —(CH 2 ) p —Y 3 —(CH 2 ) q M′, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, —C(═NR 1 )R 2 , —C(O)NR 1 R 2 , —C(O)NR′OR 2 , —C(O)OR′, —NR 1 CR 2 (═NR 3 ), —NR 1 C(═NR 2 )NR 3 R 4 , —NR 1 C(O)R 2 , —NR 1 C(O)NR 2 R 3 , —NR′C(O)OR 2 , —NR 1 S(O) 2 R 2 , —NR 1 S(O) 2 NR 2 R 3 , —NR 1 S(O) 2 NR 1 OR 3 , OH, O-aryl, SH, —S(O)(CH 2 ) 1-3 R 4 , —S(O) 2 NR 1 R 2 , —S(O) 2 NR′OR 3 , C 3 -C 7 carbocyclyl, C 6 -C 10 aryl, 5-10 membered heterocyclyl, and 5-10 membered heteroaryl.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least two R 5 are independently selected from the group consisting of halogen and OM′.

10. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein at least two R 5 are independently selected from the group consisting of (a) F and OCH 3 , or (b) C 1 and OCH 3 .

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

at least one R 5 is independently —(CH 2 ) p —Y 3 —(CH 2 ) q M′; and

Y 3 is selected from the group consisting of —NH—, —O—, —S—, —S(O)—, and —S(O) 2 —.

12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein at least one M′ is independently selected from the group consisting of CN, —CH 2 F, —CHF 2 , —CF 3 , —CH(CH 2 OH) 2 , —(CH 2 ) 3 NH 2 , —CH 2 N(CH 3 ) 2 , —C≡CH, —C≡C—CH 2 OH, —C≡C—CH 2 OCH 3 , —C≡C—CH 2 NH 2 , —C≡C—CH 2 -azetidin-1-yl, —C(O)NH 2 , OH, —S(O) 2 CH 3 , and —S(O) 2 NH 2 .

13. The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein at least one M′ is independently selected from the group consisting of cyclopropyl, azetidinyl, dioxolanyl, morpholinyl, thiadiazolyl, triazolyl, and pyridinyl, each optionally and independently substituted.

14. The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein at least one M′ is independently selected from the group consisting of cyclopropyl, azetidin-1-yl, azetidin-3-yl, dioxolanyl, morpholinyl, thiadiazolyl, triazolyl, and pyridinyl, each optionally and independently substituted.

15. The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein at least one M′ is independently selected from the group consisting of CN, C 2 -C 4 alkenyl, and C 2 -C 4 alkynyl, wherein the C 2 -C 4 alkenyl and C 2 -C 4 alkynyl are each optionally and independently substituted.

16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable salt is an alkali metal cation salt or an ammonium salt.

17. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

18. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition further comprises an additional medicament selected from the group consisting of an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, and an anti-allergic agent.

19. The pharmaceutical composition of claim 18 , wherein the additional medicament is a beta-lactam antibacterial agent selected from the group consisting of Aztreonam, Biapenem, Carumonam, Ceftazidime, Ceftibuten, Doripenem, Ertapenem, Imipenem, Meropenem, Panipenem, Tebipenem, Tigemonam,

20. A method for treating a bacterial infection in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

21. The method of claim 20 , wherein the method further comprises administering to the subject an additional medicament selected from the group consisting of an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, and an anti-allergic agent.

22. The method of claim 21 , wherein the additional medicament is a beta-lactam antibacterial agent selected from the group consisting of Aztreonam, Biapenem, Carumonam, Ceftazidime, Ceftibuten, Doripenem, Ertapenem, Imipenem, Meropenem, Panipenem, Tebipenem, Tigemonam,

23. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.